Drug intelligence / Profile preview

SK1908

Development stage: Preclinical
Lead developer: Shenzhen Sciencare Medical Industries
Modality: Small Molecules
Administration: Subcutaneous

Overview

SK1908 is a long-acting subcutaneous implant developed by Shenzhen Sciencare Pharmaceutical for the treatment of synthetic drug use disorders, specifically targeting methamphetamine and marijuana use disorders. The product is designed to provide sustained release of its active therapeutic agent over an extended period, aiming to improve patient compliance and prevent relapse in addiction recovery. SK1908 is currently in the IND-enabling phase of development and utilizes Sciencare's proprietary long-acting drug delivery technology to maintain therapeutic levels of the drug in the body.

Beyond the preview

Go deeper on SK1908.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK1908.

Explore the full profile